Abstract We developed an autologous, trileaflet tissue valve (''biovalve'') using in-body tissue architecture technology to overcome the disadvantages of current bioprosthetic valves. We designed a novel biovalve with a balloon-expandable stent: the stent biovalve (SBV). This study evaluated the technical feasibility of sutureless aortic valve replacement using the SBV in an orthotopic position, as well as the functionality of the SBV under systemic circulation, in an acute experimental goat model. Three adult goats (54.5-56.1 kg) underwent sutureless AVR under cardiopulmonary bypass (CPB). The technical feasibility and functionality of the SBVs were assessed using angiography, pressure catheterization, and two-dimensional echocardiography. The sutureless AVR was successful in all goats, and all animals could be weaned off CPB. The mean aortic cross-clamp time was 45 min. Angiogram, after weaning the animals off CPB, showed less than mild paravalvular leakage and central leakage was not detected in any of the goats. The mean peak-to-peak pressure gradient was 6.3 ± 5.0 mmHg. Epicardial two-dimensional echocardiograms showed smooth leaflet movement, including adequate closed positions with good coaptation; the open position demonstrated a large orifice area (average aortic valve area 2.4 ± 0.1 cm 2 ). Sutureless AVR, using SBVs, was feasible in a goat model. The early valvular functionalities of the SBV were sufficient; future long-term experiments are needed to evaluate its durability and histological regeneration potential.
Introduction
Advances in the treatment of heart valvular disease over the past decade have resulted in an increased probability of cure and an enhanced quality of life. Bioprosthetic valves are increasingly selected as heart valve substitutes over mechanical valves because of their associated freedom from continuous anticoagulation [1, 2] . However, bioprosthetic valves have the disadvantage of being subjected to time-related structural deterioration, especially in younger people [3] . Tissue engineered heart valves (TEHVs) have the potential to overcome this limitation [4] [5] [6] [7] . Some TEHVs have already been approved for clinical use, but only as pulmonary valves, not as aortic valves [6, 7] .
Our group developed an autologous, trileaflet tissue valve (''biovalve'') using in-body tissue architecture (IBTA) technology. IBTA technology is a novel regenerative medicine concept [8] [9] [10] [11] [12] that is based on the tissue encapsulation of foreign materials in the subcutaneous space. We believe that biovalves will become very useful aortic valve substitutes because of their good durability, even in systemic circulation in vitro and in vivo [11, 12] .
In this study, we designed a biovalve with a balloonexpandable stent; the stent biovalve (SBV), for sutureless aortic valve replacement (AVR). We evaluated the technical feasibility of sutureless AVR using SBV in the orthotopic position, and the functionality of the SBV under systemic circulation in an acute experimental goat model.
Materials and methods

Experimental approval
All animals received care that was compliant with the principles of good laboratory animal care. Our institutional animal care and use committee approved the protocols (No. 13034, 14016) used in the present study.
Preparation of the stent biovalve
In consideration of the efficiency of this preliminary study, we planned to make plural valves in one goat and reserve Fig. 1 The specially designed mold with stent for creating the stent biovalve (a). The mold is embedded in a subcutaneous pocket in a goat model (b-c). After 2 months, the mold, encapsulated with connective tissue, is harvested (d). Excess tissue is trimmed from the valve after removal of the mold (e-i). Crimped valve and its original holder (i) Fig. 2 Sutureless implantation of the stent biovalve (SBV) and the results. Native aortic valve leaflets (black arrow) are resected (a). Then, the crimped SBV (white arrow) is implanted into the aortic annulus, as indicated by three guiding sutures (black arrow) (b). The 23-mm balloon (black arrow) is inserted into the biovalve annulus and inflated with sterile water (c). The valve position, leaflet (black arrows) conditions, and coronary artery ostia are checked (d). Aortogram shows normal coronary arteries (black arrow) and less than mild paravalvular leakage (e-f). Epicardial twodimensional echocardiogram indicates adequate valve closure and good coaptation (g); the open position provides a large orifice area (h). PA pulmonary artery, RAA right atrial appendage them for use in serial AVR experiments. Thus, the AVR was actually performed using allograft valves. As described in Fig. 1 , specially designed rods with 23-mm balloon expandable stainless stents (Goodman Co., Nagoya, Japan) were implanted in subcutaneous pockets in the valve production animal under general anesthesia. Two months after implantation, we harvested the implants, which were completely encapsulated with abundant connective tissue. After removing the mold, a trileaflet structure with surrounding tubular tissue was strongly adhered to the stent. Excess tissue was trimmed from the valve, and the valve was preserved in 70 % aqueous ethanol. This valve could be crimped to a 10-mm outer diameter and it was attached to its original holder.
Sutureless AVR procedure
Three adult goats (54.5-56.1 kg) underwent sutureless AVR with SBVs. The heart was exposed via a left thoracotomy at the fourth costal bed, and a pressure line was inserted into the brachiocephalic trunk to monitor aortic blood pressure (AoP). In preparation for cardiopulmonary bypass (CPB), a heparin bolus (300 IU/kg) was injected to create a target activated coagulation time of [400 s. The aortic arch was cannulated with a 20-Fr arterial cannula, and a 25-Fr venous drainage cannula was placed into the right atrium. A 14-Fr left ventricle (LV) venting cannula was inserted into the LV. The ascending aorta was then cross-clamped, and cold cardioplegic solution was infused into the aortic root via a root cannula. The ascending aorta was opened using a transverse aortotomy. As shown in Fig. 2 , the native aortic valve leaflets were resected, and three guide sutures were placed on the nadirs of the aortic valve annulus of each cusp. Then, a crimped SBV, which was attached to its original holder, was inserted into the aortic annulus position, as indicated by the guiding sutures. The guiding sutures were tied to fix the stent strut to the aortic annulus to secure its position and prevent migration. A 23-mm balloon was then inserted into the SBV annulus, inflated with sterile water to a pressure of 4 atm, and deflated 10 s later. The positions of the SBV, leaflet damage, and the coronary ostia were checked. A running 4-0 polypropylene suture was used to close the aortotomy site, air was purged, and the aortic cross-clamp was removed. The CPB flow was then decreased and eventually stopped. If required, a catecholamine infusion was used to maintain the AoP [80 mmHg.
Angiography
Angiograms were taken after weaning each animal off CPB. Aortic regurgitation, coronary artery status, and incidence of early device migration were checked using aortography.
Epicardial two-dimensional echocardiography Epicardial two-dimensional echocardiography (Vivid E9, GE Healthcare, Horten, Norway) was performed following the angiography to assess the movement of the leaflets and to measure the aortic valve area (AVA) using echocardiographic planimetry.
Peak-to-peak pressure gradient
The LV pressure was directly monitored by a catheter. We assessed the peak-to-peak pressure gradient (pPG) by subtracting the peak LV pressure from the peak AoP.
Statistics
Quantitative data are presented as mean values ± standard deviations.
Results
Technical feasibility of the sutureless AVR
Sutureless AVR was successfully performed in all goats. There were no leaflet tears caused by crimping or coronary ostia occlusions due to the SBV observed after expanding the stents. All animals could be weaned off CPB following a mean aortic cross-clamp time of 45 min; signs of cardiac conduction abnormalities were not observed after weaning the animals off CPB.
Angiogram findings
Angiograms showed that all the valves were orthotopically located, and that they demonstrated normal opening and closing functionality. The coronary arteries were normally detected in all goats. Less than mild aortic regurgitation was observed in this study, and none of the goats demonstrated detectable central leakage (Fig. 2e-f) .
Echocardiogram findings
Epicardial two-dimensional echocardiograms showed smooth leaflet movement with wide opened positions and adequate closed positions (Fig. 2g-h ). The average AVA was 2.4 ± 0.1 cm 2 .
pPG assessment
The mean pPG was 6.3 ± 5.0 mmHg. The early two goats needed an inotropic support to maintain their AoP over 80 mmHg, after weaning off the CPB. Goat 3 did not require inotropic support.
Discussion
Reducing the immunoreaction to valve substitutes and the engraftment of regenerated valves offers the potential to overcome the disadvantages associated with current bioprosthetic valves. Several TEHV concepts have been reported, and some TEHVs are already clinically approved for use as pulmonary valve substitutes [6, 7] ; the TEHVs for aortic valves are still in development. If the functionality and durability of TEHVs can be verified, they may be useful as valve substitutes in all patients with valvular disease, including children and younger patients. Our biovalve is an autologous tissue valve created using a unique IBTA technology. The IBTA technology does not require special facilities or special management protocols. Thus, the technique is simpler and less expensive than other tissue engineering techniques. Recent advances in valve designs with stents have facilitated minimal invasive approaches in cardiac surgery [13, 14] . We adopted this technology to the biovalve and completed the AVR procedure safely in a goat model. The SBV exhibited good fixation and smooth leaflet movement under systemic circulation. Further, because the stent valve does not require a sewing cuff, the SBV was able to provide a large AVA and demonstrated low transvalvular pressure drop.
Takewa et al. [11] confirmed the long-term behavior of the biovalve in systemic circulation using a conduit type of biovalve in an apico-aortic bypass model. They found a large amount of neovascularization and the infiltration of asmooth muscle actin-positive cells into the biovalve conduit during histological evaluation. These findings indicate the possibility of biovalve self-maturation and suggest that the biovalve might acquire features such as growth adaptability. Further investigations of the histological features of the autologous biovalve in the orthotopic position and its longterm durability are ongoing.
Conclusion
AVR using a sutureless implantation technique with SBV was demonstrated to be feasible in a goat model. The early valvular function of the SBV as an aortic valve was sufficient. Long-term experiments are needed to evaluate autologous tissue SBV's durability and histological regeneration potential in an orthotopic position.
